Piotrowicz Ewa, Zieliński Tomasz, Bodalski Robert, Rywik Tomasz, Dobraszkiewicz-Wasilewska Barbara, Sobieszczańska-Małek Małgorzata, Stepnowska Monika, Przybylski Andrzej, Browarek Aldona, Szumowski Łukasz, Piotrowski Walerian, Piotrowicz Ryszard
Telecardiology Center, Institute of Cardiology, Poland
Department of Heart Failure and Transplantology, Institute of Cardiology, Poland.
Eur J Prev Cardiol. 2015 Nov;22(11):1368-77. doi: 10.1177/2047487314551537. Epub 2014 Sep 26.
The benefits of rehabilitation in heart failure (HF) patients are well established. Little is known about Nordic walking (NW) training in HF patients especially in those with cardiovascular implantable electronic devices (CIEDs).
The purpose of this study was to assess safety, effectiveness, adherence to and acceptance of home-based telemonitored NW in HF patients, including those with CIEDs (i.e. cardiac resynchronisation therapy, implantable cardioverter-defibrillator).
The study design was a single-centre, prospective, parallel-group, randomised (2:1), controlled trial among 111 HF patients, New York Heart Association (NYHA) II-III; left ventricular ejection fraction (EF) ≤ 40%. The intervention was a home-based telemonitored eight-week NW (training group (TG) n = 77) five times weekly vs usual care alone (control group (CG) n = 34). Outcome measures included a primary end point of functional capacity assessed by peak oxygen consumption (VO2peak). Secondary end points included: workload duration (t) in cardiopulmonary exercise test (CPET), six-minute walking test (6-MWT) distance and quality of life (QoL), Medical Outcome Survey Short Form 36 (SF-36); safety; adherence to and acceptance of NW. Measurements were made before and after intervention.
NW resulted in significant improvement in: VO2peak (16.1 ± 4.0 vs 18.4 ± 4.1(ml/kg/min), p = 0.0001), t (471 ± 141 vs 577 ± 158 (s), p = 0.0001), 6-MWT(428 ± 93 vs 480 ± 87 (m), p = 0.0001) and QoL (79.0 ± 31.3 vs 70.8 ± 30.3 (score), p = 0.0001). We did not observe favourable results in the CG. The differences between the TG and CG were significant in: ΔVO2peak (Δ2.0 ± 2.4 vs Δ-0.2 ± 2.1, p = 0.0004); Δt (Δ108 ± 108 vs Δ0.94 ± 109, p = 0.0031); Δ6-MWT (Δ53.8 ± 63.9 vs Δ22.0 ± 68.7, p = 0.0483). In neither group were there deaths nor necessity for hospitalisation. We did not observe any intervention from CIEDs during NW. All patients in the TG completed rehabilitation and accepted it well.
In HF patients, including those with CIEDs, home-based telemonitored NW is safe and effective. NW was well accepted by patients and adherence was high and promising.
心力衰竭(HF)患者进行康复治疗的益处已得到充分证实。对于HF患者,尤其是那些植入了心血管植入式电子设备(CIED)的患者,关于北欧式健走(NW)训练的了解甚少。
本研究旨在评估居家远程监测的NW对HF患者(包括植入CIED的患者,即心脏再同步治疗、植入式心脏复律除颤器)的安全性、有效性、依从性和接受度。
本研究设计为单中心、前瞻性、平行组、随机(2:1)对照试验,纳入111例纽约心脏协会(NYHA)II-III级的HF患者;左心室射血分数(EF)≤40%。干预措施为居家远程监测的为期8周的NW(训练组(TG)n = 77),每周进行5次,与单纯常规护理(对照组(CG)n = 34)进行对比。观察指标包括通过峰值耗氧量(VO2peak)评估的功能能力这一主要终点。次要终点包括:心肺运动试验(CPET)中的工作负荷持续时间(t)、6分钟步行试验(6-MWT)距离和生活质量(QoL),采用医学结局研究简表36(SF-36);安全性;NW的依从性和接受度。在干预前后进行测量。
NW导致以下指标显著改善:VO2peak(16.1±4.0 vs 18.4±4.1(ml/kg/min),p = 0.0001)、t(471±141 vs 577±158(s),p = 0.0001)、6-MWT(428±93 vs 480±87(m),p = 0.0001)和QoL(79.0±31.3 vs 70.8±30.3(评分),p = 0.0001)。我们在CG组未观察到良好结果。TG组和CG组之间在以下方面存在显著差异:ΔVO2peak(Δ2.0±2.4 vs Δ-0.2±2.1,p = 0.0004);Δt(Δ108±108 vs Δ0.94±109,p = 0.0031);Δ6-MWT(Δ53.8±63.9 vs Δ22.0±68.7),p = 0.0483)。两组均未出现死亡或住院需求。在NW期间,我们未观察到CIED的任何干预。TG组的所有患者均完成了康复治疗且接受度良好。
在HF患者(包括植入CIED的患者)中,居家远程监测的NW是安全有效的。NW被患者广泛接受,依从性高且前景良好。